ABEO
NASDAQ · Biotechnology
Abeona Therapeutics Inc
$6.18
+0.52 (+9.19%)
Financial Highlights (FY 2026)
Revenue
4.90M
Net Income
59.91M
Gross Margin
73.7%
Profit Margin
1,223.1%
Rev Growth
+60.4%
D/E Ratio
0.13
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 73.7% | 73.7% | 45.4% | 45.4% |
| Operating Margin | 1,081.1% | 973.0% | -8.6% | -10.0% |
| Profit Margin | 1,223.1% | 1,161.9% | -11.2% | -11.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.90M | 3.05M | 39.71M | 32.89M |
| Gross Profit | 3.61M | 2.25M | 18.02M | 14.92M |
| Operating Income | 52.95M | 29.71M | -3,427,237 | -3,280,542 |
| Net Income | 59.91M | 33.61M | -4,431,314 | -3,676,832 |
| Gross Margin | 73.7% | 73.7% | 45.4% | 45.4% |
| Operating Margin | 1,081.1% | 973.0% | -8.6% | -10.0% |
| Profit Margin | 1,223.1% | 1,161.9% | -11.2% | -11.2% |
| Rev Growth | +60.4% | +60.4% | +12.5% | +7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 17.94M | 17.94M | 47.63M | 42.47M |
| Total Equity | 142.64M | 142.64M | 217.43M | 201.44M |
| D/E Ratio | 0.13 | 0.13 | 0.22 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 55.10M | 32.63M | -4,969,444 | -4,544,257 |
| Free Cash Flow | — | — | -4,447,710 | -3,857,678 |